Mostrar el registro sencillo del ítem
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
dc.rights.license | open | en_US |
hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
dc.contributor.author | ALLARD, Camille | |
hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
dc.contributor.author | COTA, Daniela | |
hal.structure.identifier | Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB] | |
dc.contributor.author | QUARTA, Carmelo | |
dc.date.accessioned | 2024-01-30T13:47:13Z | |
dc.date.available | 2024-01-30T13:47:13Z | |
dc.date.issued | 2023-12-21 | |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/187637 | |
dc.description.abstractEn | The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of type 2 diabetes and obesity holds great promise for improving glycaemic control and weight management. Unimolecular dual and triple agonists targeting multiple gut hormone-related pathways are currently in clinical trials, with recent evidence supporting their efficacy. However, significant knowledge gaps remain regarding the biological mechanisms and potential adverse effects associated with these multi-target agents. The mechanisms underlying the therapeutic efficacy of GLP-1 receptor-based multi-agonists remain somewhat mysterious, and hidden threats may be associated with the use of gut hormone-based polyagonists. In this review, we provide a critical analysis of the benefits and risks associated with the use of these new drugs in the management of obesity and diabetes, while also exploring new potential applications of GLP-1-based pharmacology beyond the field of metabolic disease. © 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG. | |
dc.language.iso | EN | en_US |
dc.title.en | Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges | |
dc.title.alternative | Drugs | en_US |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1007/s40265-023-01982-6 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] | en_US |
dc.identifier.pubmed | 38127286 | en_US |
bordeaux.journal | Drugs | en_US |
bordeaux.hal.laboratories | Neurocentre Magendie - U1215 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | Physiopathologie de l'équilibre énergétique et obésité | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-04426481 | |
hal.version | 1 | |
hal.date.transferred | 2024-01-30T13:47:15Z | |
hal.popular | non | en_US |
hal.audience | Internationale | en_US |
hal.export | true | |
dc.rights.cc | Pas de Licence CC | en_US |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Drugs&rft.date=2023-12-21&rft.au=ALLARD,%20Camille&COTA,%20Daniela&QUARTA,%20Carmelo&rft.genre=article |
Archivos en el ítem
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este ítem. |